Bharat Biotech and Serum Institute Partnershp: India's 2 famous rival pharma companies 'Bharat Biotech' and 'Serum Institute of India' have forgotten their differences and joined hands to work together. The collaboration of these companies has taken place to eradicate polio at the global level. It is noteworthy that these two firms had made Corona vaccines 'Covishield' and 'Covaxin', whose quality had led to bitter statements from both the sides.
campaign to eradicate polio
Under this tie-up, Hyderabad company 'Bharat Biotech' will sell the drug substance of its oral polio vaccine named 'Biopolio' to Pune company 'Serum Institute of India'. India's subsidiary Bilthoven Biologicals BV, this subsidiary is based in the Netherlands.
Benefits of partnership
The purpose of this partnership is to strengthen the production and supply security of Oral Polio Vaccine (OPV) in the fight against polio as the world's target is to globally eradicate this disease. Bharat Biotech, a leading global manufacturer of OPV, has the capacity to produce up to 500 million doses annually by sourcing the drug substance from suppliers.
An official announcement on 2 April 2024 revealed that Bharat Biotech and subsidiary Bilthoven Biologicals BV have jointly acquired regulatory approval and license for commercial oral polio vaccine manufacturing in India to meet the needs of both domestic and international markets. An agreement has been signed for.
Photo Credits: Google
